AGEN:NSC-Agenus Inc. (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 3.09

Change

+0.35 (+12.77)%

Market Cap

USD 0.41B

Volume

0.46M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agenus Inc along with its subsidiaries is an immuno-oncology company. The Company is engaged in iscovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 78.92B
ARGX argenx NV ADR

N/A

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.66B
BGNE BeiGene Ltd

N/A

USD 20.24B
UTHR United Therapeutics Corporatio..

N/A

USD 16.18B
MRNA Moderna Inc

N/A

USD 16.10B
RPRX Royalty Pharma Plc

N/A

USD 15.05B
INCY Incyte Corporation

N/A

USD 13.52B
SMMT Summit Therapeutics PLC

N/A

USD 13.43B

ETFs Containing AGEN

RCRS:XETRA Rize UCITS ICAV - Rize Cy.. 5.48 % 0.00 %

N/A

USD 0.13B
BUG Global X Cybersecurity ET.. 5.31 % 0.00 %

N/A

USD 0.82B
USPY:XETRA L&G Cyber Security UCITS .. 5.15 % 0.00 %

N/A

USD 2.62B
FPXE First Trust IPOX Europe E.. 3.89 % 0.00 %

N/A

USD 3.86M
FPXI First Trust International.. 3.68 % 0.70 %

N/A

USD 0.13B
ZLU:CA BMO Low Volatility US Equ.. 2.22 % 0.33 %

N/A

CAD 1.91B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.77% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.77% 92% A 95% A
Trailing 12 Months  
Capital Gain -80.19% 15% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.19% 15% F 6% D-
Trailing 5 Years  
Capital Gain -96.00% 20% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.00% 20% F 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 52.92% 78% C+ 88% B+
Dividend Return 52.92% 78% C+ 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 476.92% 17% F 7% C-
Risk Adjusted Return 11.10% 59% D- 42% F
Market Capitalization 0.41B 38% F 32% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.46 75% 94%
Price/Book Ratio 218.61 1% 1%
Price / Cash Flow Ratio -0.29 16% 55%
Price/Free Cash Flow Ratio -2.43 65% 77%
Management Effectiveness  
Return on Equity -1,278.83% 6% 3%
Return on Invested Capital 151.25% 95% 98%
Return on Assets -21.95% 70% 24%
Debt to Equity Ratio -7.96% 79% 89%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.